$0.66
0.02% yesterday
NYSE, Nov 14, 10:10 pm CET
ISIN
US98420P3082
Symbol
XTNT

Xtant Medical Stock price

$0.65
-0.12 15.53% 1M
+0.03 5.25% 6M
+0.21 47.20% YTD
+0.20 45.27% 1Y
+0.01 1.81% 3Y
-0.61 48.25% 5Y
-31.63 97.98% 10Y
-419.35 99.84% 20Y
NYSE, Closing price Fri, Nov 14 2025
-0.01 1.20%
ISIN
US98420P3082
Symbol
XTNT

Key metrics

Basic
Market capitalization
$110.6m
Enterprise Value
$138.0m
Net debt
$27.4m
Cash
$6.9m
Shares outstanding
139.3m
Valuation (TTM | estimate)
P/E
negative | 63.9
P/S
0.9 | 0.8
EV/Sales
1.1 | 1.0
EV/FCF
negative
P/B
2.3
Financial Health
Equity Ratio
45.8%
Return on Equity
-38.3%
ROCE
0.0%
ROIC
-
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$127.8m | $132.6m
EBITDA
$4.5m | $15.8m
EBIT
$28.0k | $5.8m
Net Income
$-4.6m | $1.4m
Free Cash Flow
$-2.8m
Growth (TTM | estimate)
Revenue
15.2% | 13.0%
EBITDA
125.6% | 301.4%
EBIT
101.5% | 148.2%
Net Income
-37.5% | 108.6%
Free Cash Flow
83.9%
Margin (TTM | estimate)
Gross
60.2%
EBITDA
3.5% | 11.9%
EBIT
0.0%
Net
-3.6% | 1.1%
Free Cash Flow
-2.2%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
0.1%
Employees
225
Rev per Employee
$520.0k
Show more

Is Xtant Medical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,041 stocks worldwide.

Xtant Medical Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Xtant Medical forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Xtant Medical forecast:

Buy
88%
Hold
13%

Financial data from Xtant Medical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
128 128
15% 15%
100%
- Direct Costs 51 51
20% 20%
40%
77 77
12% 12%
60%
- Selling and Administrative Expenses 75 75
7% 7%
58%
- Research and Development Expense 2.23 2.23
4% 4%
2%
4.49 4.49
126% 126%
4%
- Depreciation and Amortization 4.46 4.46
14% 14%
3%
EBIT (Operating Income) EBIT 0.03 0.03
101% 101%
0%
Net Profit -4.58 -4.58
38% 38%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Xtant Medical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xtant Medical Stock News

Neutral
Seeking Alpha
4 days ago
Xtant Medical Holdings, Inc. ( XTNT ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Sean Browne - President, CEO & Director Scott Neils - Chief Financial Officer Conference Call Participants Kevin Gardner Ryan Zimmerman - BTIG, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good morning, everyone, a...
Neutral
PRNewsWire
4 days ago
Total Revenue of $33.3 Million Increased 19% Year-over-Year Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow Reiterates FY25 Revenue Guidance of $131-$135 Million, Representing Growth of 11%-15% over FY24 Previously Announced Sale of Certain Hardware Assets and OUS Businesses to Companion Spine Anticipated to Close by Year-End BELGRADE, Mont. , Nov. 10, 2025 /PRNewswire/ --...
Neutral
PRNewsWire
10 days ago
Launch further expands Xtant's biologics product portfolio to include surgical wound closure BELGRADE, Mont. , Nov. 5, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today announced the commercial launch of CollagenX™, its bovine collagen...
More Xtant Medical News

Company Profile

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 217 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, Interbody products and Interlaminar Stabilization products.

Head office United States
Employees 225
Website xtantmedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today